i-SENS, Inc.SA.F50A global in vitro diagnostics company that researches, develops, and produces products to support human health by leveraging advanced biosensor and electrochemical technologies.
With many years of experience in technology development, along with patents and research capabilities, i-SENS continues to develop and launch pioneering, easy-to-use products.
Our blood glucose monitoring devices have been welcomed by customers in over 110 countries, including Korea, the United States, and across Europe, thanks to their intuitive design and accuracy.
In addition, we, i-SENS, lead the diagnostic market with a diverse product portfolio, including electrolyte analyzers, blood gas analyzers, immunochemistry analyzers, and immunoassay analyzers, which are point-of-care systems capable of using whole blood.
In September 2023 in particular, we launched CareSens Air, the first continuous blood glucose monitoring device developed in Korea, providing an innovative blood glucose management solution. We are further strengthening our global position by entering overseas markets, starting with Europe in 2024.
i-SENS will always keep in mind our foundational philosophy of ‘developing and selling diagnostic products based on cutting-edge technologies to contribute to human health’ and we aim to manufacture world’s best products through seamless research and investment in core technologies.
